Iroquois Capital
VC Fund
Nashville, United States
Iroquois Capital is a private equity firm that specializes in seed to late stage, turnaround, growth capital, and PIPE investments. Investments are made available and it is offered through their broker dealers. The portfolio businesses of the company are REIT investment group, ICG captive services, commerce insurance, RIG holdings, and covenantsurgical partners. The company provides capital solutions to middle market companies.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 11%
- Fund size:
- $228M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Iroquois Capital invests in
BiotechnologyMedicalHealth CareTherapeuticsSoftware
Stages Iroquois Capital invests in
Funding RoundPost-IPO EquitySeries BSeries CDebt Financing
Countries Iroquois Capital invests in
United StatesChinaUnited Kingdom
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
H. Moore Rhett
|
|||
|
John W. Clay, Jr.
|
|||
|
Raymond Pirtle, Jr.
|
|||
William A. McGugin
|
|||
Ashley L. Holloway
|
Investment Focus
Industry
- Biotechnology 10 (53%)
- Medical 6 (32%)
- Health Care 5 (26%)
- Therapeutics 5 (26%)
- Software 4 (21%)
Stage
- Funding Round 8 (42%)
- Post-IPO Equity 6 (32%)
- Series B 1 (5%)
- Series C 1 (5%)
- Debt Financing 1 (5%)
Country
- United States 16 (84%)
- China 1 (5%)
- United Kingdom 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
H. Moore Rhett
Advisor
|
Advisor | Total investments: 0 | Find email | |
|
John W. Clay, Jr.
Advisor
|
Advisor | Total investments: 0 | Find email | |
|
Raymond Pirtle, Jr.
Advisor
|
Advisor | Total investments: 0 | Find email | |
|
William A. McGugin
President & CEO
|
President & CEO | Total investments: 1 | Find email | |
|
Ashley L. Holloway
Vice President & Controller
|
Vice President & Controller | Total investments: 0 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RS Metrics
|
Founded in 2011, RS Metrics analyzes and derives data from satellite and aerial imagery to provide fundamental insights, trends and predictive signals for businesses and investors in metals, industrials, retail and commercial real estate. RS Metrics’ proprietary, patented technology platform leverages advanced computer vision and machine learningand a scaled QC workflow to generate high quality, predictive and consumable information. Data is available in easy-to-use end-user applications, signals, and tools, and as daily data feeds for customers with quantitative focus and capabilities. For more information: Website: www.rsmetrics.com Twitter @RSMetrics Linkedin: www.linkedin.com/company/rsmetrics Medium: https://medium.com/@RSMetrics | Series B / Oct 01, 2017 | |
Covenant Physician Partners
|
Covenant Physician Partners is a privately-held owner and operator of ambulatory surgery centers. Its services include using minimally invasive and robotic technology to screen for colorectal cancers, polyp removal, and surgery of the digestive tract as well as various examinations and diagnoses of the rectum area that enable patients to get properdetection of their diseases. | $35M / Series C / Feb 08, 2013 | |
ACS Partners
|
ACS Partners provides construction services in the commercial and residential markets. ACS' services include renovations to multi-family complexes, student housing complexes, and single-family residential complexes. | Debt Financing / Jan 01, 2013 | |
Cascadian Therapeutics
|
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials,one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology. | $14.9M / Post-IPO Equity / Sep 24, 2010 | |
Raptor Pharmaceuticals
|
Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through theproprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California. | $15M / Post-IPO Equity / Aug 09, 2010 | |
Soligenix
|
Soligenix is a late-stage research and development biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The company maintains two businesssegments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early-stage development to advanced development and manufacturing. | $5.9M / Jul 02, 2010 | |
TapImmune
|
TapImmune engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAPcancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops vaccines for infectious diseases using its TAP gene technology. TapImmune has strategic relationships with University of British Columbia, Crucell Holland B.V., SAFC Pharma, Inc., and National Institute of Allergy and Infectious Diseases. The company was founded in 1999 and is based in Vancouver, Canada. | $1.3M / Post-IPO Equity / Jun 20, 2010 | |
Sevion Therapeutics
|
Sevion is a biopharmaceutical company which discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The Company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. The Company’s antibody pipeline is beingdeveloped from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multispanning membrane proteins and ion channels that play an important role in multiple diseases. The Company also developed the first protein nanocage system allowing delivery of nucleic acids and other payloads to target cells. | $11.5M / Post-IPO Equity / Mar 29, 2010 | |
Biomoda
|
Biomoda, Inc., a development state company, operates as an invitro diagnostics company that develops assays or tests to detect cancer. The company's non-invasive diagnostic is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. It also involves in developingcollection protocol and diagnostics for other cancers, including breast, oral, prostate, bladder, colorectal, and cervical. The company has an agreement with the New Mexico Institute of Mining and Technology through the New Mexico Department of Veterans Services for a clinical study for the early detection of lung cancer of the state's veterans. In addition, it has a collaborative agreement with Medical Acoustics, LLC to purchase its Lung Flute as part of the collection protocol in a clinical study. Further, the company has contracts with Quintiles Consulting and Alquest, Inc. who help to guide Biomoda through the FDA approval process. It has a strategic relationship with Obio. The company was founded in 1990 and is headquartered in Albuquerque, New Mexico. | $1M / Mar 16, 2010 | |
SinoHub
|
SinoHub, Inc. engages in electronic component sales, outsourced electronics product production and sales, and electronic component supply chain management (SCM) services in the People’s Republic of China and Hong Kong. Its electronic component sales include procurement-fulfillment and electronic component sales to manufacturers. The company’sSCM services include warehousing, delivery, and import/export. It offers SinoHub SCM, a proprietary, Web-based software system that provides order entry with automated price and category checking, order tracking, inventory management information system, shipment information system, payment system, finished orders database, operations results tracking, executive reporting system, shipment tracking, bonded inventory control system, vendor managed inventory, and VAT tracking for recovery on export. The company provides its products to contract manufacturers and design houses, as well as to OEMs and EMS companies. SinoHub, Inc. is headquartered in Shenzhen, the People’s Republic of China. | $4.6M / Feb 24, 2010 | |
| See all 19 investments → | |||
Co-Investors
Downsview Capital
5 deals together
Heights Capital Management
5 deals together
Highbridge Capital Management
5 deals together
ArmaVir Partners
5 deals together
Alpha Capital
4 deals together
Nite Capital Management
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
FAQ
What does Iroquois Capital invest in?
Iroquois Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Funding Round and Post-IPO Equity stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Iroquois Capital?
Public channels for Iroquois Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Iroquois Capital?
The team at Iroquois Capital includes H. Moore Rhett (Advisor), John W. Clay, Jr. (Advisor) and Raymond Pirtle, Jr. (Advisor), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
